Navigating the regulatory landscape for regenerative medicines in Japan
By Harriet Edwards2022-03-21T09:12:00
This is the final article in a series of three that critically analyse the differences and similarities between the regulation of advanced therapy medicinal products (ATMPs), also known as regenerative medicines…[1],[2]